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WOODRUFF AND SYMES (1962) were able to retard the growth of mouse mam-
mary carcinoma transplants, in isogenic hosts, by administration of sublethal
whole body irradiation followed by injection of allogeneic immunologically compe-
tent cells. The irradiation was given to facilitate the survival of the injected
cells which were obtained either from normal donors, or animals pre-immunized
against the tumour to be treated. Pre-immunized cells were therapeutically more
effective.
The use of immunologically competent cells in the treatment of leukaemia
transplants in isogenic mice has been reported by Alexander, Connell and Mikulska
(1966). They found that it was possible to destroy tumours by treatment, two
days after transplantation, using spleen cells from immunized allogeneic donors.
However, it was necessary to inject spleen cells in a ratio of 200 to every 1
lymphoma cell, estimated to be present.
It was hoped that after giving immunosuppressive therapy with Melphalan
(L-phenylalanine mustard), as a prelude to allogeneic spleen cell injection, a lesser
number of immunologically competent cells might suffice to produce a significant
anti-tumour effect. If this were so it would be possible to treat lymphomata at
correspondingly greater intervals after their transplantation.
MATERIALS AND METHODS
General plan of the experiments
Groups ofgenetically inbred AKR-strain mice, maintained in this department,
each received on day 0, a subcutaneous transplant of one million viable spleen
cells from an animal moribund from growth of the lymphoma. The tumour arose
spontaneously in an AKR mouse of our breeding colony and at the time of use
was in its 6th to 28th transplant generations. Viability of the tumour cell
suspensions was assessed as in Denton and Symes (1968).
In the basic experiment some of the tumour-bearing mice were set aside as
controls and the others received, on day 8, a subcutaneous injection of 5 mg. per
kg. body weight of Melphalan. This was followed, on day 9, by an intravenous
injection of spleen cells from either isogenic mice, allogeneic C57BL strain mice,
or xenogeneic " Hooded " strain rats, see Table I groups 1 to 12.
Total nucleated blood cell counts were performed on tail vein blood from each
animal in the several groups, on days 7, 11, 13 and 16. Also the day of death of
each animal was noted.PAMELA M. DENTON AND M. 0. SYMES
Variants of the basic experiment are detailed in Table I, groups 13 to 20. In
principle they comprise the earlier treatment of tumours arising from a transplant
of one million cells, or treatment on days 8 and 9 of initially smaller transplants.
Table I also shows the number oflymphoma cells used for immunization ofthe
allogeneic and xenogeneic hosts by intraperitoneal injection. Spleen cell donors,
where appropriate, were immunized nine days beforehand.
Preparation ofspleen and tumour cell suspensions
Spleen cell suspensions were prepared by the method of Woodruff and Symes
(1962) except that medium 199 (Glaxo) was substituted for Hank's solution as the
suspending medium. Tumour cell suspensions were obtained from the spleens
of mice with advanced leukaemia.
Administration of Melphalan
This was by the method of Symes (1965).
RESULTS
The serial nucleated blood cell counts, for animals in each of the several
groups, are shown in Fig. 1 to 3 and the survival times of the animals in Table I.
Animals receiving a transplant of one million leukaemic spleen cells on day 0,
followedby administration ofMelphalan and a single injection of 100 or 200 million
isogenic or immunized allogeneic or xenogeneic spleen cells, on days 8 and 9, will
be considered first.
Untreated animals, group 1, showed a steady rise in total blood count, which
had attained leukaemic proportions, (i.e. > 20 x 103 cells/cu. mm.; see Denton
and Symes, 1968), by day 11. Animals receiving Melphalan and spleen cells,
showed a striking reduction in the blood count between days 7 and 11. This was
true whether the donor cells were isogenic, compare groups 1 with 2 and 3; allo-
geneic, compare groups 1 with 4 and 5; or xenogeneic, compare groups 1 with 10
and 11. Thereafter the lymphoma cells re-appeared, so that in every instance
the blood picture became leukaemic by day 16.
Animals receiving 100 million isogenic spleen cells lived significantly longer
than the untreated controls (group 1 versus group 2), t = 3 7, n - 27, P < 0 001.
However, substitution of 100 million immunized allogeneic cells did not further
prolong survival (group 2 versus 4), t = 1 1, f* - 13 8, P < 0 3 > 0 2, nor did
immunized xenogeneic cells (group 2 versus 10) t 0 09, n - 14, P > 0*9.
The survival patterns were similar to the above when 200 million instead of 100
million spleen cells were injected (the groups 3, 5 and 11).
In an attempt to improve the outcome of treatment on days 8 and 9 after
tumour transplantation, a massive injection of 600 million immunized allogeneic
spleen cells was given by a combination of the intravenous and intraperitoneal
routes, groups 6 and 7. This procedure was unsuccessful.
In order to investigate whether the degree of immunization of the allogeneic
donors was optimal, 30 million rather than 5 million AKR lymphoma cells were
injected intraperitoneally into a group ofCS7BL mice nine days before their spleen
cells were harvested. It may be seen that a single injectoin of 100 million or
* f corrected degrees of freedom for comparison of two small samples with unequal variance.
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FIG. 1.-Graphs of the mean nucleated cell counts in AKR-strain mice, at several intervals
after transplantation of an AKR lymphoma. The experimental group, number of observa-
tions at each point, and the standard deviation of each mean are shown.
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FiG. 2. Graphs of the mean nucleated cell counts in AKR-strain mice, at several intervals
after transplantation of an AKR lymphoma. The experimental group, number of observa-
tions at each point, and the standard deviation of each mean are shown.
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200 million of such allogeneic cells, given on day 9, groups 8 and 9, produced a
similar therapeutic effect, in terms ofblood picture and host survival to allogeneic
cells from donors immunized with the smaller dose of tumour cells. However
the appearance of a leukaemic blood picture was somewhat delayed in group 8.
When two injections each of 100 million immunized allogeneic spleen cells were
given on days 9 and 13 after tumour transplantation (group 12), survival of the
treated animals was significantly reduced in comparison with those receiving
200 million isogenic cells (group 12 versus 3) t = 6-8, n = 7, P < 0 001. This
was possibly due to concomitant graft-versus-host disease.
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FIG. 3.-Graphs of the mean nucleated cell counts in AKCR-strain mice, at several intervals
after transplantation of an AKR lymphoma. The experimental group, number of observa-
tions at each point, and the standard deviation of each mean are shown.
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The earlier treatment of a transplant, consisting initially of one million
leukaemic spleen cells, by injection of Melphalan and 100 million isogenic or
immunized allogeneic spleen cells on days 4 and 5 respectively, was next investi-
gated, groups 13 and 14. Again host survival was not prolonged by the allogeneic
cells (group 13 versus 14) t 1-8, n = 7, P < 0-2 > 0-1.
However, the effect of reducing the initial size of the tumour transplant to be
treated seemed to merit further investigation.
Mice which had received 100,000 leukaemic spleen cells on day 0, were therefore
treated on days 8 and 9, groups 15 and 16. The outcome was compared with that
in appropriate untreated controls, group 17.
As in the case of similar treatments applied to an initial tumour transplant of
one million cells, Melphalan and isogenic cells prolonged host survival, although
the results just failed to reach statistical significance at the 5 per cent level (group
15 versus group 17), t 2 1, n 19, P < 0 1 > 0 05. No therapeutic advantage
was gained by substituting immunized allogeneic for isogenic cells (group 15
versus group 16) t = 0-29, n = 19, P < 0-8 > 0*7.
Finally AKR mice bearing an initial transplant of 10,000 leukaemic spleen
cells were treated on days 8 and 9 by 100 million isogenic or immunized allogeneic
spleen cells, groups 18, 19 and 20. Inthis instance although bothformsoftherapy
were associated with a fall in the blood count between days 7 and 12, neither
caused any prolongation of survival compared with untreated controls.
DISCUSSION
It seems clear that the anti-tumour effect observed, both in terms of the delay
in the appearance of a leukaemic blood picture and the prolongation of host
survival, was due to the action of the injected Melphalan and/or the isogenic
spleen cells. No additional therapeutic advantage resulted from the substitution
ofimmunized allogeneic or xenogeneic cells, in any of the variations investigated.
It therefore appears that a graft-versus-tumour reaction, mediated by foreign
immunologically competent cells (Woodruff and Symes, 1962), cannot be induced
in the present system of a transplanted lymphoma growing in its strain of origin.
This is possibly related to the lesser degree of specific antigenicity shown by the
present tumour in comparison to the one studied by Alexander et al. (1966).
SUMMARY
AKR-strain mice bearing subcutaneous transplants of an AKR lymphoma
were treated by subcutaneous injection ofMelphalan and intravenous injection of
either isogenic, allogeneic C57BL strain, or xenogeneic, " Hooded " strain rat,
spleen cells. Melphalan and isogenic cells, in some instances, resulted in a striking
reduction in the blood count, and prolongation of host survival. However no
additional therapeutic benefit was gained by substituting allogeneic or xenogeneic
cells, even though these were immunized against the tumour to be treated. It
therefore seems that the lymphoma studied is not susceptible to immunological
attack by adoptively transferred foreign lymphocytes.
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